Sign In
News Digest /
Ticker: NVO
Ticker: NVO
04:06am, Wednesday, May 06, 2026
Novo Nordisk stock jumps on stronger-than-expected Wegovy pill sales and upgraded 2026 guidance amid growing market share in the competitive U.S. weight-loss drug sector.
04:29am, Tuesday, May 05, 2026
Novo Nordisk's Wegovy pill sales are climbing fast, but rising competition and falling prices in obesity drugs, especially from Eli Lilly's new Foundayo, are putting pressure on revenue growth and market expectations.
08:24am, Wednesday, Apr 29, 2026
As Eli Lilly rolls out its weight-loss drug Foundayo, investors await clear sales data. Early reports suggest a slower uptake compared to rivals, but comprehensive insights remain weeks away.
09:02am, Monday, Mar 09, 2026
Stock futures drop sharply amid Middle East tensions pushing oil above $100; Hims & Hers jumps on Novo deal; Kalshi and Polymarket eye $20B valuations; HP Enterprise earnings await.
08:54am, Monday, Mar 09, 2026
Novo Nordisk partners with Hims to offer FDA-approved Wegovy and Ozempic at self-pay prices, dropping its lawsuit amid competition with compounded drug alternatives.
08:03am, Wednesday, Feb 04, 2026
Novo Nordisk's stock tumbled following a lowered 2026 sales outlook impacted by U.S. price cuts and patent expirations, signaling challenges ahead despite 2025 growth.
07:11am, Wednesday, Jan 28, 2026
Novo Nordisk poured nearly $500M into US ads for Wegovy and Ozempic in early 2025, spending more than twice as much as Eli Lilly on competing obesity and diabetes drugs.
08:05am, Thursday, Nov 13, 2025
Telehealth player Mangoceuticals partners with Eli Lilly and Novo Nordisk, launching digital programs to sell blockbuster GLP-1 weight-loss drugs, sparking a 32% jump in its shares.
06:25am, Monday, Nov 10, 2025
Norway's sovereign wealth fund abstains from crucial Novo Nordisk board vote amid leadership reshuffle. Meanwhile, Pfizer clinches $10B deal for Metsera, sidelining Novo in obesity drug race.
08:49am, Wednesday, Nov 05, 2025
Novo Nordisk pares down growth projections for Ozempic and Wegovy as pricing pressure and competition intensify, sparking mixed reactions in a volatile market environment.
08:33am, Wednesday, Nov 05, 2025
Wall Street futures edged down amid anxiety over stretched valuations and mixed earnings reports from chipmakers and insurers, with traders watching closely ahead of key U.S. jobs data and ongoing government shutdown tensions.
09:12am, Tuesday, Nov 04, 2025
Pfizer outperforms Q3 earnings forecasts and raises full-year profit guidance even as sales decline, driven by strategic cost cuts and ongoing challenges in the Covid product line.
08:56am, Friday, Oct 24, 2025
Novo Nordisk's board upheaval hands chairman Lars Rebien Sørensen unmatched authority amid market share slump and competition surge from Eli Lilly, stirring investor unease and governance debate.
02:27am, Wednesday, Oct 22, 2025
Novo Nordisk's board chair Helge Lund and six independent directors resign following clashes with controlling shareholder over company strategy. Former CEO returns as interim chair during restructuring.
08:03am, Monday, Oct 06, 2025
Eli Lilly (LLY) to invest over $1B in India to ramp drug manufacturing via contract partners, open a Hyderabad manufacturing & quality hub and hire technical staff-aiming to ease supply gaps amid U.S. tariffs and rising GLP‑1 generic competition.
07:31am, Monday, Sep 22, 2025
Pfizer to Buy Metsera for Up to $7.3B - $47.50/Share Cash (43% Premium), Metsera Pops ~56% Premarket
Pfizer to buy Metsera for up to $7.3B - $47.50/share plus $22.50 in milestones (~43% premium). Metsera jumped ~56% premarket. Deal fast-tracks Pfizer into the obesity drug race with Eli Lilly and Novo Nordisk.
02:35am, Wednesday, Sep 10, 2025
Novo Nordisk to cut ~9,000 jobs (11.5%) to save DKK8bn (~$1.26bn); DKK9bn restructuring hit trims operating profit growth guidance to 4-10% (from 10-16%). Wegovy/Ozempic face Eli Lilly competition; shares down ~46% YTD.
06:21am, Friday, Aug 29, 2025
Denmark cuts 2025 GDP to 1.4% (from 3%) as Novo Nordisk's GLP‑1 slowdown and US tariff-hit exports weigh; export growth trimmed to 0.9% (from 4.3%). 2026 GDP forecast raised to 2.1%.
07:34am, Tuesday, Aug 19, 2025
Health Canada cleared Novo Nordisk's Ozempic to slow diabetic kidney disease, reduce kidney-failure risk and cut cardiovascular deaths in T2D - Canada's first GLP‑1 with this label. Uptake hinges on reimbursement, pricing and competition.
07:36am, Friday, Aug 08, 2025
European stocks rose 0.2%, marking their biggest weekly gain in three months as Novo Nordisk surged 4.6% on strong obesity drug data. Positive earnings and Fed rate cut bets boosted markets, despite weakness in German insurers and Eli Lilly shares.
06:26am, Thursday, Aug 07, 2025
The Trump administration is urging pharma firms to raise drug prices overseas, especially in Europe, to lower U.S. costs, pushing "most favored nation" pricing amid complex trade talks and industry resistance to domestic price cuts.
07:02am, Wednesday, Aug 06, 2025
Trump's tariff moves reshape global trade, easing EU tensions but hiking duties on copper and low-value imports. Key deadlines in August-September may escalate US-China friction and pressure drugmakers like Eli Lilly and Pfizer on pricing.
07:08am, Wednesday, Jul 30, 2025
Novo Nordisk shares plunged 23% after naming insider Maziar Doustdar as CEO and cutting 2025 sales growth forecasts due to weaker U.S. demand for Wegovy and Ozempic amid rising competition from compounded GLP-1 therapies.
05:22am, Monday, May 12, 2025
U.S.-China trade optimism boosts stock futures, with tariffs set to drop significantly. Dow futures rose 785 points as investors await the CPI report. Meanwhile, energy prices climb, but healthcare stocks falter due to potential drug price cuts. Stay informed!
04:13am, Monday, Jan 27, 2025
Upcoming earnings reports this week include SAP, Novo Nordisk, T-Mobile, ServiceNow, Visa, Mastercard, Exxon, AbbVie, and Chevron. Analysts predict key insights from these companies, impacting market trends. Stay tuned for updates!
08:50am, Wednesday, Jan 08, 2025
Greenland's Prime Minister Mute Egede meets Denmark's King Frederik amid U.S. President Trump's interest in acquiring the Arctic island. As tensions rise, implications for markets, particularly in defense and trade, warrant close attention from stock traders.
07:18am, Monday, Dec 23, 2024
Novo Nordisk (NVO) surges 8% after Friday's plunge; European markets rise as the trading week kicks off ahead of the Christmas holidays.
09:26am, Wednesday, Dec 18, 2024
Novo Holdings has acquired Catalent for $16.5 billion, expanding its influence in contract drug manufacturing. This strategic move could enhance revenue growth for Novo Nordisk and present new trading opportunities amid shifting market dynamics.
06:11am, Monday, Dec 16, 2024
Novo Nordisk (NYSE: NVO) plans to invest 8.5 billion Danish crowns ($1.2 billion) in a new manufacturing facility in Odense, Denmark, focusing on rare disease therapies. The plant, set to create 400 jobs by 2027, boosts Novo’s growth amid rising stock performance.
08:42am, Monday, Nov 11, 2024
Stock futures rise as Tesla reclaims a $1 trillion market cap. Dow, S&P 500, and Nasdaq futures show gains after a strong week, drawing investor optimism.
04:23am, Wednesday, Nov 06, 2024
Major companies reporting earnings today, November 6, 2024, include Novo Nordisk (NVO), Toyota (TM), QUALCOMM (QCOM), Gilead (GILD), and MercadoLibre (MELI). Investors await insights and trends that could influence market strategies.
06:14am, Tuesday, Nov 05, 2024
EU regulators will decide by December 6 on Novo Holdings’ acquisition of Catalent. The deal, vital for expanding obesity drug production, faces scrutiny from both EU and U.S. bodies, potentially reshaping the competitive pharmaceutical landscape.
03:55am, Monday, Nov 04, 2024
Key earnings reports are set for the week of November 4, 2024. Watch for Vertex Pharmaceuticals, Palantir Technologies, and QUALCOMM on November 6. Also, Toyota, Novo Nordisk, Arista Networks, and Duke Energy will report, impacting investor strategies.
08:48am, Friday, Sep 27, 2024
Friday Market Recap: S&P 500 sets new record as Chinese tech stocks rally on economic stimulus. Key U.S. inflation and consumer data ahead. Oil prices rise on global output shifts.
06:07am, Thursday, Sep 26, 2024
Evotec's stock surged 6% to €6.250 after announcing a partnership with Novo Nordisk to advance cell therapy technology. This collaboration promises substantial financial backing, boosting trader confidence in Evotec's growth potential.
06:35am, Tuesday, Sep 24, 2024
Novo Nordisk CEO Lars Jorgensen faces scrutiny from Senator Bernie Sanders over high U.S. prices for Ozempic and Wegovy, with cash costs exceeding $1,000 monthly. In response, Jorgensen cites R&D investments and favorable insurance coverage, while market dynamics evolve.
05:03am, Monday, Aug 19, 2024
Eli Lilly's Zepbound, a groundbreaking GLP-1 agonist, is quickly becoming a blockbuster, complementing Mounjaro and competing with Novo Nordisk. With the obesity treatment market expected to reach $100 billion by 2030, Eli Lilly is a compelling long-term investment.
07:13am, Thursday, Aug 08, 2024
Eli Lilly (NYSE: LLY) raises 2024 profit forecasts following Zepbound's record $1B quarterly sales. With a 32% stock surge this year and aggressive production plans, Eli Lilly is poised for growth in the booming weight-loss market. Investors should watch closely.
03:36am, Wednesday, Aug 07, 2024
Novo Nordisk (NYSE: NVO) reported mixed Q2 results, raising its 2024 sales forecast but falling short on operating profit amid rising competition from Eli Lilly in the obesity sector. Traders should stay alert to this evolving market landscape.
